Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Sabra Health Care REIT Inc. (SBRA)

NASDAQ: SBRA · Real Estate Investment Trusts · Tustin, CA

Our rating: Positive

Call changed from Neutral to Positive at $20.35, moderate conviction, November 3, 2026.

Breaks if: The Positive call turns Cautious if the next two quarterly filings show year-over-year revenue growth falling below 8% — indicating the 2026 acceleration was non-recurring rather than a durable operational turn — or if AFFO, once disclosed in a subsequent filing, covers the stated dividend by less than 90 cents on the dollar. It turns Neutral sooner if leverage metrics emerging from the 10-Q filed 2026-11-02 imply a refinancing wall that would reduce FFO by more than 10% from the current run rate at prevailing benchmark rates.

Key figures

Market value$5.3B
Revenue, last 12 months$497M
Net income, last 12 months$72M
Free cash flow, last 12 monthsn/a
Price to earnings74.7×
Free cash flow yieldn/a
Dividend yield5.9%
Operating marginn/a
Return on equity2.5%
Beta to the S&P 5000.07
Volatility, annualized23.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$143M55.6%$0.11n/a
June 30, 2026$129M63.1%$-0.10n/a
March 31, 2026$117M50.7%$0.16n/a
December 31, 2025$108M41.1%$0.11n/a
September 30, 2025$92M24.8%$0.09n/a
June 30, 2025$79M16.3%$0.27n/a
March 31, 2025$77M17.3%$0.17n/a
December 31, 2024$77M25.5%$0.20n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 33 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.